Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Brady Trevisan"'
Autor:
Martin Rodriguez, Brady Trevisan, Ritu M. Ramamurthy, Sunil K. George, Jonathan Diaz, Jordan Alexander, Diane Meares, Denise J. Schwahn, David R. Quilici, Jorge Figueroa, Michael Gautreaux, Andrew Farland, Anthony Atala, Christopher B. Doering, H. Trent Spencer, Christopher D. Porada, Graça Almeida-Porada
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract Hemophilia A is the most common X-linked bleeding disorder affecting more than half-a-million individuals worldwide. Persons with severe hemophilia A have coagulation FVIII levels 3 years post-treatment. Cells engraft in major organs, and no
Externí odkaz:
https://doaj.org/article/85e8ab404d0141858837af84107b16bc
Autor:
Brady Trevisan, Martin Rodriguez, Hailey Medder, Shannon Lankford, Rebecca Combs, John Owen, Anthony Atala, Christopher D. Porada, Graça Almeida-Porada
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
IntroductionHemophilia A (HA) is the most common X-linked bleeding disorder, occurring in 1 in 5,000 live male births and affecting >1 million individuals worldwide. Although advances in protein-based HA therapeutics have improved health outcomes, cu
Externí odkaz:
https://doaj.org/article/59c44bce82bc4c60bc3be1f87a9f1c9f
Autor:
Nadia El-Akabawy, Martin Rodriguez, Ritu Ramamurthy, Andrew Rabah, Brady Trevisan, Alshaimaa Morsi, Sunil George, Jordan Shields, Diane Meares, Andrew Farland, Anthony Atala, Christopher B. Doering, H. Trent Spencer, Christopher D. Porada, Graça Almeida-Porada
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 17, Iss , Pp 465-477 (2020)
The delivery of factor VIII (FVIII) through gene and/or cellular platforms has emerged as a promising hemophilia A treatment. Herein, we investigated the suitability of human placental cells (PLCs) as delivery vehicles for FVIII and determined an opt
Externí odkaz:
https://doaj.org/article/921693f95a664e1dbedad0c986f3c1d3
Autor:
Brady Trevisan, Alshaimaa Morsi, Julio Aleman, Martin Rodriguez, Jordan Shields, Diane Meares, Andrew M. Farland, Christopher B. Doering, H. Trent Spencer, Anthony Atala, Aleks Skardal, Christopher D. Porada, Graça Almeida-Porada
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 9 (2021)
Microfluidic technology enables recapitulation of organ-level physiology to answer pertinent questions regarding biological systems that otherwise would remain unanswered. We have previously reported on the development of a novel product consisting o
Externí odkaz:
https://doaj.org/article/c35027b575a04190af7a027ec4d06850
Publikováno v:
Semin Cell Dev Biol
The ability to study the behavior of cells, proteins, and cell-cell or cell-protein interactions under dynamic forces such as shear stress under fluid flow, provides a more accurate understanding of the physiopathology of hemostasis. This review touc
Autor:
Andrew M. Farland, Sunil George, Christopher D. Porada, Martin Rodriguez, Andrew Rabah, Anthony Atala, Alshaimaa Morsi, Brady Trevisan, H. Trent Spencer, Jordan E Shields, Graça Almeida-Porada, Diane Meares, Nadia El-Akabawy, Ritu M Ramamurthy, Christopher B. Doering
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 17, Iss, Pp 465-477 (2020)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
The delivery of factor VIII (FVIII) through gene and/or cellular platforms has emerged as a promising hemophilia A treatment. Herein, we investigated the suitability of human placental cells (PLCs) as delivery vehicles for FVIII and determined an opt
Autor:
John Owen, Sunil George, M. Graca Almeida-Porada, Christopher B. Doering, Brady Trevisan, Jacqueline Dizon, Rebecca Combs, Anthony Atala, Martin Rodriguez, Jordan E Shields, H. Trent Spencer, Christopher D. Porada, Shannon Lankford
Publikováno v:
Blood. 138:3966-3966
We have previously reported that normal juvenile sheep that received weekly intravenous (IV) infusions of human (n=3) or an expression/secretion-optimized, bioengineered human/porcine hybrid (ET3) FVIII protein (n=3) for 5 weeks (20 IU/kg) developed
Autor:
Jordan E Shields, John Owen, Martin Rodriguez, M. Graca Almeida-Porada, Jorge P. Figueroa, H. Trent Spencer, Diane Meares, Anthony Atala, Christopher D. Porada, Brady Trevisan, Christopher B. Doering, Sunil George
Publikováno v:
Blood. 138:1863-1863
We have previously reported that in utero transplantation (IUTx) of sheep fetuses (n=14) with human placental cells (PLC) transduced with a lentiviral vector encoding mcoET3, an expression/secretion-optimized, bioengineered fVIII transgene (PLC-mcoET
Autor:
Andrew Rabah, Brady Trevisan, H. Trent Spencer, Diane Meares, Sunil George, Michael D. Gautreaux, Jorge P. Figueroa, Martin Rodriguez, Denise J. Schwahn, Christopher D. Porada, Ritu M Ramamurthy, Anthony Atala, M. Graca Almeida-Porada, Jordan E Shields, Christopher B. Doering, John Owen
Publikováno v:
Blood. 136:1-2
The treatment of hemophilia A (HA) patients by prenatal transplantation (PNT) is a feasible, yet underestimated and unexplored clinical approach. The procedure, similar to that of an amniocentesis, poses minimal risk to both the fetus and the mother.
Autor:
Anthony Atala, Christopher D. Porada, Jorge P. Figueroa, Shannon Lankford, H. Trent Spencer, Sunil George, John Owen, Christopher B. Doering, M. Graca Almeida-Porada, Martin Rodriguez, Brady Trevisan, Diane Meares, Jordan E Shields
Publikováno v:
Blood. 136:34-34
Hemophilia A (HA) is characterized by a decrease in the functional clotting protein factor VIII (FVIII). Current hemophilia treatments consist of either prophylactic or on-demand administration of FVIII protein. Despite the vast improvements and avai